transfusion-related immunomodulation
Conditions
Interventions
Group 1: The aim of this study is to investigate the effect of allogeneic blood transfusions on the inflammatory activity of immune cells. For this purpose, different surgical patient collectives will
Sponsors
Universitätsklinikum Heidelberg
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: - Written consent - any of the following medical treatments: o above-knee amputation o coronary artery bypass grafting (CABG) o surgical transcatheter aortic valve implantation (TAVI) o critical care (
Exclusion criteria
Exclusion criteria: - Pregnancy - Sepsis (diagnosis within 3 days ahead of screening) - leukemia - Therapy with immune checkpoint inhibitors - Inclusion in an interventional study - Infectious viral diseases (HBV, HCV, HIV, COVID-19) - Iatrogenic immunosuppression
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Expression of inflammatory biomarkers (PD-1, CTLA-4, TIM-3, CD200 und CD200R on T-cells and monocytes) before and after allogeneic blood transfusion as well as 24 hours after transfusion. Expression is analyzed by flow cytometry. The fluorescence intensity (MFI) of the investigated biomarkers serves as a parameter for the qualitative and quantitative determination of the expression level and thus as the main target criteria. | — |
Secondary
| Measure | Time frame |
|---|---|
| Basic demographic and clinical data such as medical history data, routine clinical laboratory, drug therapy, microbiological/infectious disease findings. | — |
Countries
Germany
Contacts
Public ContactDania Fischer
Universitätsklinikum Heidelberg
Outcome results
None listed